Schering/Genome Therapeutics asthma collaboration valued at up to $67 mil..
SCHERING/GENOME THERAPEUTICS ASTHMA AGREEMENT VALUED AT UP TO $67 MIL. will use genomics for the discovery of new asthma treatments. Waltham, Mass.-based Genome Therapeutics will use its high-throughput positional cloning, bioinformatics and genomics sequencing capabilities to identify genes and associated proteins for Schering-Plough to use in developing pharmaceuticals. Schering and Genome Therapeutics also have an anti-infectives research collaboration worth up to $43.5 mil. that was announced a year ago ("The Pink Sheet" Dec. 11, 1995, T&G-19).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth